Quarterly report pursuant to Section 13 or 15(d)

STOCK COMPENSATION

v3.21.2
STOCK COMPENSATION
3 Months Ended
Jun. 30, 2021
Equity [Abstract]  
STOCK COMPENSATION

8. STOCK COMPENSATION

 

The following tables summarize share-based compensation expenses relating to RSUs and stock options and the effect on basic and diluted loss per common share during the three month periods ended June 30, 2021 and 2020: 

           
    Three Months
Ended
June 30, 2021
    Three Months
Ended
June 30, 2020
 
Vesting of stock options and restricted stock units   $ 120,154     $ 84,207  
Total stock-based compensation expense   $ 120,154     $ 84,207  
                 
Weighted average number of common shares outstanding – basic and diluted     12,828,816       9,632,977  
                 
Basic and diluted loss per common share attributable to stock-based compensation expense   $ (0.01 )   $ (0.01 )

 

All of the stock-based compensation expense recorded during the three months ended June 30, 2021 and 2020, which totaled $120,154 and $84,207, respectively, is included in payroll and related expense in the accompanying condensed consolidated statements of operations. Stock-based compensation expense recorded during the three months ended June 30, 2021 and 2020 represented an impact on basic and diluted loss per common share of $(0.01) and $(0.01), respectively.

 

We review share-based compensation on a quarterly basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of adjusting the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The effect of forfeiture adjustments for the three months ended June 30, 2021 was insignificant.

 

Stock Option Activity

 

During the three months ended June 30, 2021, we issued a stock option grant to our CEO for the purchase of 266,888 shares of our common stock under our 2020 Plan. The purchase price for the shares subject to the option is $5.17 per share, the fair market value of the common stock on the date of the grant. The shares subject to the option are subject to vesting over four years, commencing on the date of grant, or Vesting Commencement Date, with twenty-five percent (25%) of the shares subject to the option vesting on the first anniversary of the Vesting Commencement Date and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, in each case subject to Dr. Fisher’s Continuous Service (as defined in the 2020 Plan) through each vesting date.

 

We did not issue any stock options during the three months ended June 30, 2020.

 

Options outstanding that have vested as of June 30, 2021 and options that are expected to vest subsequent to June 30, 2021 are as follows: 

                 
    Number of
Shares
    Weighted
Average
Exercise
Price
    Weighted
Average
Remaining
Contractual
Term in
Years
 
Vested     87,210     $ 8.83       8.29  
Expected to vest     926,449     $ 2.76       9.43  
Total     1,013,659                  

  

A summary of stock option activity during the three months ended June 30, 2021 is presented below: 

                 
    Amount     Range of
Exercise Price
    Weighted
Average
Exercise
Price
 
Stock options outstanding at March 31, 2021     844,089     $ 1.28 - 142.50     $ 3.07  
Exercised     (11,562 )   $ 2.45     $ 2.45  
Granted     266,888     $ 5.17     $ 5.17  
Cancelled/Expired     (85,756 )   $ 2.45 - 18.75     $ 7.22  
Stock options outstanding at June 30, 2021     1,013,659     $ 1.28 - 142.50     $ 2.76  
Stock options exercisable at June 30, 2021     87,210     $ 1.28 - 142.50     $ 8.83  

 

On June 30, 2021, our stock options had an intrinsic value of approximately $1,664,000 based on our closing share price of $4.92 on that date.

 

At June 30, 2021, there was approximately $3,722,000 of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted average period of 7.7 years.